The Clorox Company
Pro Forma Disclosure for 8-K
(millions)
The following unaudited pro forma condensed consolidated statements of earnings reflect adjustments to Clorox’s historical consolidated statement of earnings for the year-ended June 30, 2004 and the three month period ended September 30, 2004 to give effect to:
The exchange of a Clorox subsidiary for Henkel KGaA’s, a major shareholder, interest in Clorox common stock as if it had occurred on July 1, 2003.
The transitional services to be provided by Clorox to Henkel, including some interim production of insecticides and Soft Scrub.
The issuance of long-term debt to reduce outstanding commercial paper balances initially used to fund the exchange transaction.
The following unaudited pro forma condensed consolidated balance sheet reflects adjustments to Clorox’s historical consolidated balance sheet at September 30, 2004 to give effect of this exchange, as if it has occurred on September 30, 2004.
PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (UNAUDITED)
The Clorox Company
Three-month period ended September 30, 2004 | As Reported | Effect of Share Exchange | | Other Pro Forma Adjustments | | Pro Forma |
|
In millions, except share and per-share amounts | | | | | | |
Net sales | $1,090 | $(42) | | $- | | $1,048 |
Cost of products sold | 605 | (14) | | - | | 591 |
|
|
Gross profit | 485 | (28) | | - | | 457 |
Selling and administrative expenses | 132 | (2) | | - | | 130 |
Advertising costs | 108 | (3) | | - | | 105 |
Research and development costs | 21 | - | | - | | 21 |
Restructuring and asset impairment costs | 30 | - | | - | | 30 |
Interest expense | 8 | - | | 20 | (i) | 28 |
Other (income) expense, net | (3) | 3 | | - | | - |
|
|
Earnings from continuing operations before income taxes | 189 | (26) | | (20) | | 143 |
Income taxes | 66 | (9) | (k) | (7) | (j) | 50 |
|
|
Earnings from continuing operations | $123 | $(17) | | $(13) | | $93 |
|
|
Earnings per common share | | | | | | |
Basic | | | | | | |
Continuing operations | 0.58 | | | | | 0.62 |
| | | | | | |
Diluted | | | | | | |
Continuing operations | 0.57 | | | | | 0.61 |
| | | | | | |
Weighted average common shares outstanding (in thousands) | | | | | | |
Basic | 212,905 | | | | | 151,499 |
Diluted | 215,117 | | | | | 153,712 |
PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (UNAUDITED)
The Clorox Company
Year ended June 30, 2004 | As Reported | Effect of Share Exchange | | Other Pro Forma Adjustments | | Pro Forma |
|
In millions, except share and per-share amounts | | | | | | |
Net sales | $4,324 | $(162) | | $33 | (l) | $4,195 |
Cost of products sold | 2,387 | (56) | | 29 | (l) | 2,360 |
|
|
Gross profit | 1,937 | (106) | | 4 | | 1,835 |
Selling and administrative expenses | 552 | (9) | | - | | 543 |
Advertising costs | 429 | (9) | | - | | 420 |
Research and development costs | 84 | (1) | | - | | 83 |
Interest expense | 30 | - | | 77 | (m) | 107 |
Miscellaneous, net | 2 | 11 | | - | | 13 |
|
|
Earnings from continuing operations before income taxes | 840 | (98) | | (73) | | 669 |
Income taxes | 294 | (32) | (o) | (27) | (n) | 235 |
|
|
Earnings from continuing operations | $546 | $(66) | | $(46) | | $434 |
|
|
| | | | | | |
Earnings per common share | | | | | | | |
Basic: | | | | | | | |
Continuing operations | 2.58 | | | | | 2.90 | |
| | | | | | | |
Diluted | | | | | | | |
Continuing operations | 2.55 | | | | | 2.85 | |
| | | | | | | |
Weighted average common shares outstanding (in thousands) | | | | | | | |
Basic | 211,683 | | | | | 149,669 | |
Diluted | 214,371 | | | | | 152,358 | |
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)
The Clorox Company
As of September 30, 2004, In millions | As Reported | Pro Forma Adjustments | | Offering Adjustments | | Pro Forma |
|
Assets | | | | | | |
Current assets | | | | | | |
Cash and cash equivalents ......................................................................................... | $255 | $(2,105) | (a, c) | $2,111 | (c, g) | $261 |
Receivables, net ........................................................................................................ | 385 | - | | - | | 385 |
Inventories ............................................................................................................... | 305 | - | | - | | 305 |
Other current assets.................................................................................................. | 53 | - | | - | | 53 |
Assets held for exchange.......................................................................................... | 132 | (132) | (a) | - | | - |
|
|
Total current assets .................................................................................................... | 1,130 | (2,237) | | 2,111 | | 1,004 |
|
|
Property, plant and equipment, net ............................................................................. | 995 | - | | - | | 995 |
|
|
Goodwill, net ............................................................................................................... | 736 | - | | - | | 736 |
|
|
Trademarks and other intangible assets, net ................................................................. | 602 | - | | - | | 602 |
|
|
Other assets ................................................................................................................. | 309 | - | | - | | 309 |
|
|
Total assets ................................................................................................................. | $ 3,772 | $(2,237) | | $2,111 | | $ 3,646 |
|
|
Liabilities and Stockholders’ Equity | | | | | | |
Current liabilities | | | | | | |
Notes and loans payable ........................................................................................... | $170 | - | | 471 | (g) | $641 |
Current maturities of long-term debt ........................................................................ | 3 | - | | - | | 3 |
Accounts payable ..................................................................................................... | 287 | - | | - | | 287 |
Accrued liabilities ..................................................................................................... | 617 | 6 | (h) | - | | 623 |
Income taxes payable ............................................................................................... | 18 | - - | | - | | 18 |
|
|
Total current liabilities .......................................................................................... | 1,095 | 6 | | 471 | | 1,572 |
|
|
Long-term debt ........................................................................................................... | 474 | - | | 1,640 | (g) | 2,114 |
|
|
Other liabilities ............................................................................................................ | 385 | - | | - | | 385 |
|
|
Deferred income taxes ................................................................................................. | 174 | (8) | (b) | - | | 166 |
|
|
Stockholders’ equity | | | | | | |
Common stock | 250 | - | | - | | 250 |
Additional paid-in capital ......................................................................................... | 304 | - | | - | | 304 |
Retained earnings ..................................................................................................... | 2,906 | 582 | (d) | - | | 3,488 |
Treasury shares, at cost | (1,552) | (2,843) | (e) | - | | (4,395) |
Accumulated other comprehensive net losses ........................................................... | (252) | 26 | (f) | - | | (226) |
Unearned compensation ........................................................................................... | (12) | - | | - | | (12) |
|
|
Stockholders’ equity .................................................................................................... | 1,644 | (2,235) | | - | | (591) |
|
|
Total liabilities and stockholders’ equity ...................................................................... | $3,772 | $(2,237) | | $2,111 | | $3,646 |
|
|
Pro Forma Adjustments
Balance sheet adjustments:
Reflects the elimination of assets and liabilities being transferred to Henkel.
Reflects the income tax benefit from the release of deferred tax liabilities.
Reflects estimated transaction costs of $7.
Reflects the estimated gain on the transaction, including the release of deferred tax liabilities of $8 and estimated transaction costs of $7.
Reflects the treasury shares expected to be purchased by the Company in the agreed upon transaction with Henkel, including $4 of estimated share repurchase costs.
Reflects the estimated $26 translation impact of HIBSA, and other entities.
Reflects the expected issuance of commercial paper of $2,121, of which $1,650 will be refinanced shortly after with long-term debt. The long-term debt is net of estimated loan issuance costs of $10.
The share exchange agreement includes a purchase price adjustment based on the working capital balance at the date of the close. The entry reflects the estimated purchase price adjustment.
Statement of earnings adjustments for the three months ended September 30, 2004:
Reflects 3 months of interest expense and debt issuance amortization expense on $471 of commercial paper and $1,650 of long-term debt expected to be issued to fund this transaction. The weighted average interest rate on the commercial paper and long-term debt are estimated to be 1.5% and 4.1%, respectively.
Reflects the estimated incremental tax benefit for federal and state taxes from interest expense using a 37.4% effective tax rate.
Reflects the estimated blended domestic and international effective tax rates for the transferred business and HIBSA
Statement of earnings adjustments for the year ended June 30, 2004:
Reflects the estimated net sales and cost of products sold from the transitional services with Henkel.
Reflects 12 months of interest expense and debt issuance amortization expense on $471 of commercial paper and $1,650 of long-term debt expected to be issued to fund this transaction. The average weighted average interest rate on the commercial paper and long-term debt are 1.1% and 4.1%, respectively.
Reflects the estimated incremental tax benefit for federal and state taxes from interest expense using a 37.4% effective tax rate.
Reflects the estimated blended domestic and international effective tax rates for the transferred business and HIBSA.